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Abstract 
 Multiple sclerosis (MS) has long been characterized as an inflammatory disease of the 
central nervous system (CNS); however, recent research has suggested that neurodegenerative 
processes such as oxidative stress may be the primary force driving disease progression and 
associated neuropsychological impairment in this population.  Recent work by our research 
group identified GSH, an important cerebral antioxidant, as a marker of oxidative stress-
mediated neurodegeneration in patients with secondary progressive (SP) MS.  However, the 
present study featured the first comparison of cerebral GSH concentrations among patients with 
RR, PP, and SP subtypes of MS and healthy controls.  The primary aims of this study were to 
examine differences in GSH concentrations among subtypes of MS and to investigate whether 
reductions in GSH concentrations occurred in conjunction with neuropsychological impairments 
in processing speed, memory, and executive function.  Results indicated that relative to RR 
patients, progressive (PP and SP) patients exhibited the largest reductions in GSH 
concentrations, with no significant differences between PP and SP patients.  A similar pattern of 
outcomes was observed on the neuropsychological measures, with reductions in GSH being 
accompanied by a worsening of impairment in processing speed and a broadening of impairment 
to include deficits in learning and memory.  These results support the hypothesis that even in the 
absence of inflammatory processes underlying acute clinical exacerbations, diffuse oxidative 
stress signals an ongoing neurodegenerative process that likely contributes to disease progression 
and cognitive decline over the course of the disease. 
 
Keywords: multiple sclerosis, oxidative stress, glutathione, GSH, cognitive dysfunction, 
magnetic resonance spectroscopy, neuropsychological assessment 
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Glutathione as a Predictor of Neuropsychological Impairment in Patients with Relapsing 
Remitting, Secondary Progressive, and Primary Progressive MS 
 Multiple sclerosis (MS) is a chronic, progressive disease characterized by 
neuroinflammation and neurodegeneration of the central nervous system (CNS).  While the 
clinical profiles of patients with MS can be quite varied, upwards of 70% of patients report some 
level of neuropsychological dysfunction during the course of the disease (Kurtzke et al., 1972; 
Peyser, Rao, LaRocca, & Kaplan, 1990; Rao, Leo, Bernardin, & Unverzagt, 1991), with slowed 
speed of information processing cited as one of the most pervasive cognitive deficits observed in 
this population (Archibald & Fisk, 2000; Bergendal, Fredrikson, & Almkvist, 2007; Bodling, 
Denney, & Lynch, 2008, 2009, 2012; De Sonneville et al., 2002; DeLuca, Chelune, Tulsky, 
Lengenfelder, & Chiaravalloti, 2004; Demaree, DeLuca, Gaudino, & Diamond, 1999; Denney, 
Gallagher, & Lynch, 2011; Denney & Lynch, 2009; Kail, 1997, 1998; Kujala, Portin, Revonsuo, 
& Ruutiainen, 1994; Lengenfelder et al., 2006; Lynch, Dickerson, & Denney, 2010; Macniven et 
al., 2008; Rao, St. Aubin-Faubert, & Leo, 1989; Reicker, Tombaugh, Walker, & Freedman, 
2007; Schulz, Kopp, Kunkel, & Faiss, 2006).  While these deficits have long been established 
within the literature, the relationship between neurological impairment and neuropsychological 
dysfunction has been tenuous, and many of the most common physical or neurological indicators 
of disease progression (e.g., enhancing lesions in the brain) are often only mildly correlated with 
cognitive dysfunction (Filippi, M., et al., 1994; Lynch, Parmenter, & Denney, 2005; Ryan, Lee, 
Clark, & Campbell, 1996; Zivadinov et al., 2001).  Fortunately, over the past decade, 
improvements in both magnetic resonance (MR) and neuropsychological assessment techniques 
have afforded increasingly sensitive methods for capturing some of the hallmark neurological 
and neuropsychological deficits in this population.  One of these emerging techniques is 
 
2	  
magnetic resonance spectroscopy (MRS), a non-invasive, in vivo imaging technique that 
measures cerebral metabolite concentrations.  Studies evaluating the neurochemical profiles of 
patients with neurological disorders have become increasingly common in several literatures, 
including Alzheimer’s and aging (e.g., Loos, Achten, & Santens, 2010; Parnetti et al., 1997; 
Valenzuela & Sachdev, 2001) and provide some advantages over using traditional magnetic 
resonance imaging (MRI; e.g., T1- and T2-weighted images).  Recent work by our MS research 
group has used MRS techniques to measure one particular molecule of interest, glutathione 
(GSH).  A recent pilot study demonstrated that GSH may provide a reliable marker of disease 
progression in patients with the secondary progressive (SP) subtype of MS (Choi, Lee, Denney, 
& Lynch, 2010).  Yet, to date, no studies have explored the degree to which GSH correlates with 
other common features of MS, particularly neuropsychological impairment.  Moreover, it is 
unclear how MS might impact GSH levels in relapsing remitting (RR) and primary progressive 
(PP) subtypes.  The present study will be the first to examine the relationship between 
neuropsychological impairment and GSH levels in patients with RR, PP, and SP subtypes of MS.  
The following sections will review inflammatory and neurodegenerative processes hallmark to 
MS, introduce the concept of oxidative stress as it relates to neurodegeneration in each subtype 
of MS, explore the role of GSH as a marker of oxidative stress-mediated neurodegeneration, and 
review the current understanding of the relationship between neuropsychological impairment and 
neurobiological markers of disease progression. 
Background 
 MS has long been conceptualized, and likewise treated, as predominantly a 
neuroinflammatory, demyelinating disease of the CNS.  However, important distinctions arise 
between MS subtypes that are relevant when considering the relative contributions of 
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inflammatory and neurodegenerative processes to MS pathology.  MS has most commonly been 
divided into three subtypes: RR, PP, and SP (Lublin & Reingold, 1996).  While the conceptual 
descriptions of these categories are fairly distinct, in practice, classifying patients as to subtype 
can be challenging. 
 RR patients vary considerably in presentation, with some patients presenting with 
frequent, debilitating clinical exacerbations, while others having relatively few relapses; 
however, the general course is characterized by a series of relapses, or periods of exacerbated 
symptoms most commonly attributed to the development of a new lesion in the CNS.  Because 
enhancing lesions are believed to be caused by acute inflammation of myelinated neuronal axons 
(Fassbender et al., 1998; Lin & Blumhardt, 2001; van Walderveen et al., 1999), and because the 
RR subtype is characterized by the development of enhancing lesions, most of the support for 
viewing MS as an inflammatory disease centers on this subtype.  However, in RR patients, rates 
of relapses and recovery following relapses are highly variable.  While functional recovery 
follows most relapses, the speed and degree of recovery varies from patient to patient.  In 
addition to the inflammatory processes occurring at this stage of the disease, neurodegenerative 
processes may also contribute to the diverse symptomatology.  Indeed, axonal loss, and grey and 
white matter atrophy have been observed in RR patients, although to a lesser extent than more 
progressive subtypes (Simon et al., 1999; Wegner & Stadelmann, 2009).  For RR patients, it is 
unclear whether these neurodegenerative features are occurring secondary to or independent of 
inflammation. 
 For many RR patients, the number of new enhancing MS lesions tends to decrease over 
time, and patients begin to experience a gradual worsening of symptoms that cannot be explained 
by the presence of enhancing lesions.  At this stage of progressive worsening, patients are 
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unlikely to have as many distinct relapses and are less likely to recover from those relapses that 
occur.  For many patients, the typical disease course evolves over time from the RR subtype to 
the secondary progressive (SP) subtype.  Researchers believe that this shift in symptomatology 
marks a clear distinction between inflammatory and neurodegenerative processes in MS (Pittock 
& Lucchinetti, 2007; Trapp & Nave, 2008).  In fact, recent studies have demonstrated that 
neurodegeneration can occur in the absence of inflammation and is likely to occur in patients 
with progressive forms of the disease (Pirko, Lucchinetti, Sriram, & Bakshi, 2007; Simon et al., 
1999; Trapp & Nave, 2008).  However, proponents of the inflammation theory have also 
observed long-lasting enhancing lesions among SP patients and have continued to view 
inflammation as a continuous process underlying disease progression in this progressive subtype.   
 In contrast to SP patients, PP patients experience gradual deterioration from the onset of 
the disease, with no relapses or periods of functional recovery.  Although physical symptom 
presentation for PP patients is very similar to, and sometimes indistinguishable from SP subtype, 
the onset of symptoms constitutes a clear clinical difference between these patients.  Due to the 
gradual worsening of symptoms observed at the onset of the disease, researchers suggest that the 
PP subtype may provide evidence for neurodegeneration.  While the relative contributions of 
inflammation and neurodegeneration are currently under debate, mounting evidence suggests 
that neurodegeneration may have a much more prominent role in all subtypes of MS than 
previously thought (Pirko et al., 2007; Simon et al., 1999; Wegner & Stadelmann, 2009). 
 Oxidative stress and glutathione.  A multitude of factors likely contribute to 
neurodegeneration in MS, including neurochemical disturbances such as glutamate excitotoxicity 
and oxidative stress (Bains, & Shaw, 1998; Coyle & Puttfarcken, 1993; Smythies, 1999).  
Oxidative stress is defined as the imbalance between the accumulation of reactive oxygen 
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species in the brain and the brain’s capacity to detoxify and prevent subsequent neural damage 
(Ramalingam & Kim, 2012; Coyle & Puttfarcken, 1993).  An increase in cerebral free radicals 
leads to oxidative damage and can have a significant impact on cognitive function (Beal, 1995; 
Harman, 1992). 
 Despite the brain’s high susceptibility to oxidative stress, the brain also contains 
numerous antioxidants to scavenge reactive oxygen species and maintain metabolic stability.  
One such antioxidant is GSH, a tripeptide enzymatic substrate composed of L-glutamate, L-
cysteine, and glycine.  GSH is a major endogenous antioxidant produced by the cells (Meister & 
Anderson, 1983; Pompella, Visvikis, Paolicchi, De Tata, & Casini, 2003).  It plays a crucial role 
in maintaining other important antioxidants such as vitamins C and E and is used in biochemical 
reactions such as DNA synthesis and repair, protein synthesis, amino acid transport, and enzyme 
activation (Meister, 1983).  GSH is pervasive throughout mammalian cells and has been 
implicated in metabolic disturbances observed in other neurodegenerative disorders (Bains & 
Shaw, 1997; Coyle & Puttfarcken, 1993). 
 In the presence of oxidative stress, GSH combines with reactive oxygen species to reduce 
the neurodegenerative impact of free radicals on cells.  As GSH reacts with free radicals, it 
becomes oxidized, resulting in lower concentrations of GSH (Cooper & Kristal, 1997).  A 
reduction in GSH generally signifies an increase in oxidative stress, and, potentially, an increase 
in oxidative-stress-related neurodegeneration (Heales, Davies, Bates, & Clark, 1995).  Thus, as 
opposed to using magnetic resonance imaging (MRI) techniques (e.g., T1- and T2-weighted 
images) that are more sensitive to the inflammatory features of MS (e.g., gadolinium-enhancing 
lesions), measuring GSH levels in the brain may provide a reliable method for quantifying 
neurodegenerative features of the disease. 
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 While quantifying GSH can be quite challenging, investigators in our MS research group 
at the University of Kansas Medical Center have developed techniques for isolating GSH 
resonance signals from other cerebral metabolites (Choi, 2003a; 2003b; 2004).  There are 
generally two ways to express GSH levels: as a ratio to creatine (Cr) levels, or as an absolute 
quantity.  Using the former procedure assumes that Cr levels remain comparable between MS 
patients and controls, while the latter does not require this assumption.  Researchers have 
debated whether GSH and other brain metabolites of interest should be quantified as ratios to Cr 
or as absolute quantities.  While there is no gold standard for this measure, a recent review 
maintained that, for most studies, differences in Cr between MS patients and controls have been 
minimal and that expressing GSH levels as ratios to Cr is an acceptable practice (Caramanos, 
Narayanan, & Arnold, 2005). 
 Oxidative stress and MS subtypes.  Because oxidative stress may provide a marker of 
neurodegeneration, it is useful to consider the theories and implications of oxidative stress within 
different subtypes of MS.  There are several theories for how inflammatory and 
neurodegenerative processes interact to produce the neurological and neuropsychological 
disability observed in MS (Schulz, Lindenau, Seyfried, & Dichgans, 2000).  The first, and 
historically most common theory stipulates that MS begins as an inflammatory disease; however, 
as the disease progresses and lesion load increases, oxidative stress becomes more prevalent, 
resulting in subsequent axonal neurodegeneration.  Presumably, in this scenario, oxidative stress 
may not be observed until several years after disease onset and would typically be concomitant 
with progressive subtypes.  An alternative theory states that oxidative stress-induced 
neurodegeneration occurs early on in the disease, as a separate process from inflammation.  
Several investigators have supported this hypothesis, noting widespread metabolic abnormalities 
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in normal appearing white matter (NAWM) that occur early and, importantly, are evident even 
during clinical remission (i.e., an absence of inflammation; Kirov et al., 2009; Inglese et al., 
2003).  This scenario could account for the highly heterogeneous disease course observed in RR 
patients, where oxidative stress contributes to many of the deficits observed in RR patients and is 
not necessarily related to enhancing lesion load.  In this case, oxidative stress would likely be 
present, to some extent, early in the disease course and could potentially predict subsequent grey 
and white matter atrophy.  A third theory, and one that has been vigorously debated within the 
literature, states that MS begins as a neurodegenerative disease, and that oxidative stress triggers 
the immune response responsible for inflammation and demyelination.  In this scenario, 
oxidative stress would precede the development of enhancing lesions, and might even serve as a 
reliable predictor of inflammatory disease processes (Cooper & Kristal, 1997; Heales et al., 
1999). 
 Given the emerging support for GSH as a marker of oxidative stress-mediated 
neurodegeneration, measuring GSH in vivo using MRS may provide a novel way to characterize 
neurodegeneration in all three subtypes of MS.  If neurodegeneration is the predominant process 
underlying MS, as some emerging research has suggested, changes in GSH could be observed in 
all subtypes of MS, with lower levels of GSH being associating with greater neurodegeneration 
(Choi et al., 2010).  In this case, GSH measures would probably not be highly correlated with 
neuroinflammatory markers (e.g., gadolinium-enhancing lesions in traditional MRI scans); 
however, GSH would be correlated with other more firmly established neuroimaging measures 
of neurodegeneration (e.g., atrophy), disability status, and neuropsychological performance. 
 Neuropsychological impairment in MS.  In addition to neurochemical and 
neuroanatomical indicators of MS disease progression, neuropsychological measures have also 
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become central areas of focus in the MS literature.  Several prominent literature reviews have 
cited a host of cognitive symptoms associated with MS (e.g., Brissart et al, 2012; Chiaravalloti & 
DeLuca, 2008; Jongen, Ter Horst, & Brands, 2012; Julian, 2011; Langdon, 2011), including 
problems with attention, information processing speed, executive functioning, and memory.  To 
date, deficits in processing speed have been observed using several types of assessment tools, 
including reaction time (RT), rapid serial processing (RSP), and planning time measures.  While 
most researchers agree that processing speed is the most common domain impacted by MS, some 
investigators have proposed that slowed processing speed may account for apparent deficits in 
other domains (Denney & Lynch, 2009; Hughes, Denney, & Lynch, 2011).  This overlap 
becomes most evident in patients with significantly diminished processing speed, where apparent 
deficits in working memory or executive functioning emerge because patients are unable to 
process information at a rate necessary to effectively encode the information or process it at a 
higher level (Denney, Hughes, Owens, & Lynch, 2012).  While researchers may disagree over 
the relative primacies of domain-specific deficits (e.g., processing speed versus memory), there 
is strong evidence that essential verbal skills and general intelligence are rarely affected by MS.  
These important distinctions noticeably separate MS-related cognitive impairments from those of 
other neurological disorders, including Alzheimer’s and other dementias, where one finds 
pervasive deficits in language, memory, and reasoning. 
 In addition to identifying and describing these deficits across MS patients in general, 
research over the past decade has sought to more specifically differentiate subtypes of MS with 
regard to neuropsychological impairment.  However, because distinguishing MS subtypes can be 
challenging even at the neurological level, only a handful of studies have attempted to directly 
compare cognitive deficits between subtypes.  Huijbregts et al. (2006) demonstrated that while 
 
9	  
patients with progressive (PP and SP) subtypes performed worse than controls on all tasks of the 
Brief Repeatable Battery of Neuropsychological Tests, RR patients only performed worse on 
speeded tasks that required higher-order processes (e.g., Word List Generation).  A similar 
distinction was noted between SP and PP patients, where both groups exhibited poor 
performance relative to controls, but SP patients performed worse than PP patients on those same 
higher-order processing tasks.  Potagas et al. demonstrated a similar finding, where RR patients 
or patients with clinically isolated syndrome (CIS) generally exhibited fewer deficits in verbal 
learning and memory relative to more progressive subtypes.  De Sonneville also demonstrated 
significant deficits in attention and processing speed that were more severe in progressive 
patients relative to RR patients, with no significant differences emerging between PP and SP 
patients.  These results suggest a general worsening of cognitive impairment in conjunction with 
disease progression, particularly within the domain of processing speed. 
 In addition to cognitive deficits, emotional dysfunction has also been observed in patients 
with MS.  Although the mechanism underlying depression in MS is not entirely understood, 
reviews have cited neurotransmitter dysfunction as a result of neuronal damage as a primary 
biological pathway (Feinstein, 2011; Vattakatuchery, Rickards, & Cavanna, 2011).  Furthermore, 
because MS is a chronic illness, research on coping has identified depression as a potential risk 
factor in patients with poor coping skills (Goretti, Portaccio, Zipoli, Razzolini, & Amato, 2010).  
Regardless of the mechanism, depression, stress, and fatigue are frequently reported among 
patients with MS.  Therefore, assessing these areas of emotional functioning is critical for 
understanding whether patients’ neuropsychological dysfunction stems predominantly from 
depressive features or directly from impairments in the aforementioned cognitive domains. 
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 Numerous studies have investigated relationships between cognitive deficits and 
neurobiological changes associated with MS.  However, to date, most of these studies have 
employed broad neuropsychological screeners with poor sensitivity to MS-specific deficits and 
neuroimaging measures that focus on neuroinflammatory processes.  While these screeners are 
generally fast and easy to administer, they may not detect some of the more subtle deficits 
common to patients with MS (e.g., decreased processing speed).  Similarly, neuroimaging 
techniques that neglect neurodegenerative processes may be missing a key event driving disease 
progression.  These results suggest the need for more targeted neuropsychological assessment 
and the use of neuroimaging techniques that capture neurodegenerative processes. 
The Present Study 
 By and large, the majority of MS neuroimaging studies have focused on structural 
differences observed between MS patients and healthy controls, with an emphasis on 
inflammatory processes.  Recently, MRS techniques for measuring cerebral metabolic processes 
have become more common in the literature, and several studies have cited abnormalities in 
metabolites such as myo-inositol (mI), glutamate (Glu), choline (Cho), creatine (Cr), and n-
acetyl-aspartate (NAA) in patients with MS (e.g., De Stefano & Filippi, 2007; Kirov et al., 2009; 
Aboul-Enein, Krssak, Hofterger, Prayer, & Kristoferitsch, 2010).  However, little is known about 
GSH and the correlations between GSH and performance on neuropsychological measures.  
Therefore, the present study was the first to investigate the relationship between oxidative stress, 
as measured by GSH levels, and neuropsychological impairment in RR, PP, and SP MS patients.  
Moreover, this investigation employed a battery of computerized neuropsychological evaluations 
specifically designed to assess MS-related deficits in processing speed, verbal and visual 
memory, and executive function.  In collaboration with investigators at the Hoglund Brain 
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Imaging Center at the University of Kansas Medical Center, in vivo GSH levels were quantified 
and examined in relation to performance on each cognitive measure. 
 The present study was the first to critically assess differences between healthy controls 
and MS patients (RR, PP, and SP subtypes) with regard to in vivo GSH levels and selected 
neuropsychological measures of processing speed, memory, and executive function.  The 
primary aims of this study were the following: (a) to evaluate GSH concentrations among patient 
groups and healthy controls in order to investigate the role of neurodegeneration in disease 
progression; (b) to examine whether neuropsychological measures displayed a similar pattern of 
outcomes; and (c) to examine correlations between GSH levels and neuropsychological 
measures.  We propose the following hypotheses: (a) that GSH concentrations will be lower for 
patients relative to controls, with concentrations being lowest in progressive patients; (b) that 
reductions in GSH concentrations will be accompanied by cognitive impairments, particularly by 
slowed information processing speed; and (c) that GSH levels will be at least modestly correlated 
with neuropsychological outcomes and disease-related variables (e.g., disability status). 
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Method 
Participants 
 The original sample comprised a total of 15 RR (11 females, 4 males), 15 PP (5 females, 
10 males), and 16 SP (12 females, 4 males) patients with clinically definite MS and 19 healthy 
individuals (10 females, 9 males) of comparable demographics.  MS patients ranged in age 
between 18 and 65, with disease durations ranging between 1 and 33 years.  Disability ratings 
based on the Expanded Disability Status Scale (EDSS; Kurtzke, 1983) ranged from 1 to 8.5.  The 
healthy controls ranged in age between 24 and 65.  Of the 65 total participants, movement 
artifact prevented the acquisition of GSH metabolite concentration in 19 individuals, yielding a 
final sample of 12 RR (10 females, 2 males), 13 PP (5 females, 8 males), and 11 SP (8 females, 3 
males) MS patients and 10 (8 females, 2 males) healthy controls.  For these remaining 
participants, MS patients ranged in age between 18 and 63, with disease durations ranging 
between 1 and 33 years.  Disability ratings ranged from 1 to 8.5.  The healthy controls ranged in 
age between 24 and 65. 
 All patients were under the care of the same neurologist (Sharon G. Lynch) at the 
University of Kansas Medical Center, and had been diagnosed with MS for at least one year 
prior to recruitment (in order to ensure accurate diagnosis).  Consistent with prior studies in our 
laboratory, exclusionary criteria for patients were as follows: presence of any neurological 
disorder other than MS; history of drug or alcohol abuse, premorbid psychological disorder (e.g., 
depression), mental retardation, or head injury; visual acuity greater than 20/50 (corrected) or 
impaired color vision; symptomatic involvement of the hands; MS relapse within the past 30 
days; or cognitive impairment of sufficient severity to interfere with comprehension of testing 
instructions.  Additionally, because this study required participants to undergo an MRI, 
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additional exclusionary criteria were as follows: presence of cardiac or pacemaker, cardiac 
defibrillator, heart valve replacement, aneurysm/vascular clips, stints/filters/coils, kidney/liver 
transplant, kidney disease or diabetes, BB/foreign body/gunshot wound, neurostimulation device, 
permanent hearing aid, cochlear implant, medication skin patch, vascular IV access, 
hydrocephalus/spinal shunt, Harrington rods, eyelid spring/wire, permanent prosthetic device, 
dentures/partials, motion disorder, permanent body piercing(s), permanent eyeliner, bladder 
stimulation device, insulin pump, implantable device, or history of metal in the eyes.  For female 
patients, pregnancy or presence of magnetic intrauterine device constituted additional 
exclusionary criteria.  The same exclusionary criteria applied for healthy controls. 
Measures 
 Demographic, self-report, and disease-related measures.  The following information 
was collected from each participant on a demographic information form: name, date of birth, 
age, years of education, occupation, marital status, race/ethnicity, and handedness.  Additionally, 
MS subtype, number of years since their initial diagnosis (disease duration), and EDSS rating 
was collected for MS patients.  The demographic information form was followed by self-report 
questionnaires, which included the Beck Depression Inventory – Fast Screen (BDI-FS; Beck, 
1996; Benedict, Fishman, McClellan, Bakshi, & Weinstock-Guttman, 2003), the Fatigue 
Severity Scale (FSS; Krupp, LaRocca, Muir-Nash, & Steinberg, 1989), and the Perceived Stress 
Scale (PSS; Cohen, Kamarck, & Mermelstein, 1983).  Each MS patient additionally completed 
the Multiple Sclerosis Neuropsychological Questionnaire – Patient Form (MSNQ; Benedict, et 
al., 2004), a measure of subjective cognitive impairment. 
 Expanded Disability Status Scale.  The EDSS provided a measure of each MS patient’s 
current level of disability.  Functional status in each of eight categories (e.g., cerebral, brainstem, 
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cerebellar) was rated and combined to form a total EDSS score.  Scores on this measure range 
from “0” to “10,” with “0” being “normal neurological exam” and “10” being “death due to 
MS.”  Only MS patients were evaluated for EDSS. 
 Beck Depression Inventory–Fast Screen.  The BDI-FS measured participants’ perceived 
severity of depressive symptoms occurring over the past two weeks.  Items on this scale 
corresponded to the psychological and non-somatic criteria for diagnosing major Depressive 
Disorders in the Diagnostic and Statistical Manual of Mental Health Disorders – Fourth Edition 
(DSM-IV; American Psychological Association, 2000), and exclude somatic criteria (e.g., 
psychomotor slowing) that may be more closely related to MS.  The BDI-FS consists of seven 
items, each rated on a scale of “0” to “3,” with “0” indicating no symptoms and “3” indicating 
severe symptoms.  The total score on this measure is the sum of all items.  Scores range from 0 
to 21, with “0 to 3” being minimal symptoms, “4 to 6” being mild symptoms, “7 to 9” being 
moderate symptoms, and “10 to 21” being severe symptoms. 
 Fatigue Severity Scale.  The FSS assessed participants’ self-report of fatigue over the 
past seven days.  The scale consists of nine items (e.g., “Exercise brought on my fatigue), each 
rated on a scale of “1” to “7,” with “1” being “strongly disagree” and “7” being “strongly agree.”  
The total score on this measure is an average of the nine items, with higher scores indicating 
greater fatigue. 
 Perceived Stress Scale.  The PSS assessed the frequency with which participants have 
experienced daily stressful situations over the past month.  The scale consists of 10 items, each 
rated on a scale of “0” to “4”, with “0” being “never” and “4” being “very often.”  The total 
score on this measure is the sum of all items, including four reverse-scored items, with higher 
scores indicating greater perceived stress. 
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 Multiple Sclerosis Neuropsychological Questionnaire – Patient Form.  The MSNQ 
measured the frequency with which MS patents believe they have experienced cognitive 
weaknesses or impairment over the past three months.  The scale consists of 15 items, each rated 
on a scale of “0” to “4,” with “0” being “never” and “4” being “very frequent.”  The total score is 
the sum of all items, with higher scores indicating more frequent cognitive problems. 
 Neuropsychological assessments.  Following completion of the initial demographic and 
self-report measures, participants completed a fixed battery of five computerized 
neuropsychological tests: The Rey Auditory Verbal Learning Test (RAVLT; Rey, 1964), the 
Tower of London (TOL; Krikorian, Bartok, Gay, 1994; Shallice, 1982), the Stroop Test (Stroop, 
1935), the Symbol Digits Modalities Test (SDMT; Smith, 1982), and the Brief Visuospatial 
Memory Test - Revised (BVMT; Benedict, Schretlen, Groninger, Dobranski, & Sphritz, 1996).  
These five tests yielded a total of 13 scores, each of which fell into one of three cognitive 
domains: processing speed, memory, or executive function.  Processing speed measures assessed 
reaction time (RT), rapid serial processing (RSP), and planning time (PT).  Memory measures 
assessed verbal and visual recall and recognition.  Executive function measures assessed 
planning and attentional control.  
 Rey Auditory Verbal Learning Test.  This is a computerized version of the RAVLT 
designed to assess verbal memory.  On this test, participants were asked to listen to a list of 
aurally presented words that the examiner read from the computer screen.  The first list, List A, 
comprised fifteen unrelated words.  After each presentation, the participant was asked to verbally 
recall as many words from the list as he or she could recall.  After the third trial, the examiner 
read a second list, List B, of 15 “distractor” words and the participant was asked to verbally 
recall as many of those words as possible.  The participant was then asked to immediately recall 
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as many words as possible from List A.  A delayed visual recognition trial of 50 words was 
performed 20 to 30 minutes after the recall, with each word presented individually on the screen.  
In this trial, the participant was instructed to press the “1” key if the word had been on the 
original word list (List A) and to press the “3” key if the word was not on the original list.  Four 
scores were generated from this test: the total number of words recalled during the first three 
learning trials (Rey-A), the total number of words recalled during the immediate recall task 
(Rey-IR), the total number of correct delayed recognition responses (Rey-DR), and the response 
latencies (in seconds) for each delayed recognition item (Rey-DRRT).  In terms of cognitive 
domain classifications, the Rey-DRRT provided an RT measure of processing speed and the 
Rey-A, Rey-IR, and Rey-DR provided measures of verbal learning and memory.  While lower 
scores on the Rey-DRRT indicated faster speed, higher scores on the remaining measures 
indicated better learning and memory performance. 
 Tower of London.  This computerized version of the TOL was designed to assess 
executive function (i.e., planning and strategic problem solving).  In the bottom portion of the 
screen, three colored disks were arranged on three pegs (starting position).  The upper portion of 
the screen displayed a model of the disks in a different arrangement (ending position).  The 
participant was instructed to move the blocks in the lower portion of the screen to match the 
arrangement displayed in the upper portion of the screen, and to do so as quickly as possible and 
using a predetermined number of moves.  The test consisted of 16 items ranging from 2-move to 
5-move problems.  Each problem was scored as one point for correct responses and zero points 
for incorrect responses.  Two scores were generated from this test.  The total sum of all item 
scores (TOL-Score) provided a measure of executive function (planning), and average planning 
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time (TOL-PT) provided a measure of processing speed (planning time).  While greater TOL-
Score scores indicated better performance, lower TOL-PT scores indicated faster planning. 
 Stroop Test.  This computerized test was adapted from the original Stroop Color-Word 
Interference Test (Golden, 1978).  It consisted of three 60-second trials.  In the first trial, 
participants were asked to read a series of color words (e.g., “RED”) printed in black letters.  In 
the second trial, participants were asked to name the colors used to print a row of four X’s.  In 
the third trial, participants were asked to name the colors used to print an incongruent color word 
(e.g., BLUE printed in red letters).  Participants responded verbally to items and pressed the 
space bar as quickly as possible to advance to the next item.  The computer timed each trial and 
recorded the number of items completed in each trial.  Four scores were generated from this test: 
the number of items completed in the first trial (Stroop-W), the number of items completed in the 
second trial (Stroop-C), a combined core for the first two trials (Stroop-WC), and relative 
interference (i.e., attentional control) score (Stroop-RI; Denney & Lynch, 2009).  The Stroop-W, 
Stroop-C, and Stroop-WC provided RSP measures of processing speed and the Stroop-RI 
provided a measure of executive function.  While higher scores on the trials indicated better 
performance, lower scores on the Stroop-RI indicated better attentional control. 
 Symbol Digit Modalities Test (SDMT).  This computerized test was adapted from the 
paper-based SDMT (Smith, 1982).  The test consisted of a single 90-second trial.  During this 
test, a reference key was located at the top of the computer screen displaying nine nondescript 
geometric symbols with their corresponding digits (i.e., 1-9).  Stimulus items consisted of 
symbols presented individually in the center of the computer screen.  Participants were asked to 
state the number associated with the stimulus, and press the space bar to display the next item.  
The computer timed the trial and recorded the number of responses.  Additionally, an Incidental 
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Learning (IL) trial was added to our computerized version of the SDMT in order to evaluate 
participants’ acquisition of the associations between symbols and digits during the course of the 
preceding trial.  Participants were shown a stimulus item without the reference key and were 
asked to say “yes” and press the “1” key if they saw the item on the previous reference key, and 
“no” and press the “3” key if they did not.  If they responded “yes,” a list of numbers 1 through 9 
appeared on the screen and participants were asked to identify the number that went with the 
symbol.  If they responded “no,” the next stimulus item appeared on the screen.  Two scores 
were derived from this measure: the total number of responses on the initial 90-second trial 
(SDMT) and the total number of correct number of responses on the IL trial (SDMT-IL).  In 
terms of cognitive domain classification the SDMT provided an RSP measure of processing 
speed and the SDMT-IL provided a measure of visual memory.  As in the case with the RAVLT, 
higher SDMT scores indicated better performance, while lower SDMT-IL scores indicated faster 
response times. 
 Brief Visuospatial Memory Test.  This computerized test was adapted from the paper-
based BVMT-R (Benedict, 1997).  The test consisted of three visuospatial memory trials, where 
the participant was shown a 2x3 grid of six geometric shapes that appeared on the computer 
screen for 10 seconds.  The participant was then asked to identify the six stimulus items from an 
array of 18 geometric shapes and to identify the position on the grid where each stimulus had 
been displayed.  This trial was repeated two additional times.  Participants were awarded two 
points for each correctly placed item and one point for each incorrectly placed item.  The total 
sum of all item scores provided a measure of visual memory (BVMT), with higher scores 
indicating better performance. 
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 Neuroimaging procedures.  All MR scans were performed using a 3T scanner (Skyra, 
Siemans, Erlangen, Germany) at the Hoglund Brain Imaging Center located at the University of 
Kansas Medical Center.  Participants were asked to lie supine in the MR scanner for the duration 
of all scans.  Data acquisition consisted of a series of MRS scans, followed by a series of MRI 
scans.  However, for the purpose of this study, we will only focus on the MRS scans. 
 MRS data acquisition.  Participants were positioned for GSH chemical shift imaging 
(CSI) using a FLASH sequence of three-plane scout images such that the volume of interest 
(VOI), a 6 x 6 x 3-cm axial slab covering just above the corpus callosum, was placed in the iso-
center of the magnet (Figure 1).  MRS scans used a custom-made helmet coil designed to target 
frontal and parietal regions.  Preliminary localized automated shimming was performed using the 
Massachusetts General Hospital shimming package to ensure homogeneity across the CSI slice.  
B0 and B1 mapping were performed to correct for signal variations caused by frequency shifts on 
GSH signals or any field inhomogeneities of the RF coil.  GSH signals were measured using an 
MQ/SQ CSI sequence (TE/TR = 115/1500ms, FOV = 20cm, matrix = 12 x 12, slice thickness = 
3cm), and an axial slice including frontal and parietal regions was imaged. 
 Concentrations of GSH were calculated using a gold standard internal reference method 
(Choi, Lee, Merkle, & Shen, 2004; 2006), the GSH-to-creatine (Cr) ratio.  The phase and 
frequency of GSH signals in each voxel of CSI were corrected based on those of Cr signals in the 
corresponding voxels using a custom-written program and IDL software (RSI, Boulder, CO).  
Frontal and parietal GSH concentrations were determined by overlaying the GSH data to 
anatomical MRI scans.  In total, three GSH measures were obtained for the present study: a 2x4 
voxel matrix corresponding to the frontal region, a 2x4 voxel matrix corresponding to the 
parietal region, and a 4x4 voxel matrix comprising the combined frontoparietal region (Figure 1). 
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Figure 1.  (A) Outline of glutathione (GSH) chemical shift imaging (CSI) slice, the volume of 
interest (VOI), overlaid on a T1-weighted sagittal scout image of the brain.  (B) Partial views of 
4x4 frontoparietal voxel matrices for in vivo GSH CSI (left) and simultaneously measured 
creatine (Cr) CSI (right).
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Procedures 
 This study was approved by the Human Subjects Committee at the University of Kansas 
Medical Center.  MS patients were recruited during the course of their regularly scheduled 
appointments at the MS Clinic.  After obtaining written consent and having the participant fill 
out an MRI safety form, a research assistant scheduled a time for the patient to return for their 
study appointment.  Control participants were recruited through friends and family members of 
patients, research personnel, and employees at the University of Kansa Medical Center.  Age and 
gender of control subjects was monitored in order to obtain approximate equivalency on these 
variables.  Study appointments began with the administration of the demographic and self-report 
questionnaires, followed by the computerized neuropsychological assessments and finally the 
series of MR scans.  In total, study procedures lasted approximately three hours. 
Analyses 
 Preliminary Analyses.  A preliminary omnibus analysis was performed to assess group 
differences (controls, RR, PP, SP) on demographic characteristics (gender, years of education, 
age), and self-report measures (BDI-FS, FSS, PSS).  Variables that resulted in significant F 
statistics were further evaluated with a series of planned comparisons using Helmert contrasts.  
For the first contrast, controls were compared with all MS subtypes combined.  The second 
contrast compared RR and combined progressive subtypes (PP and SP).  Finally, the third 
contrast evaluated differences between PP and SP subtypes.  The justification for these contrasts 
lies in evidence garnered from previous studies that (a) MS patients, regardless of subtype, often 
differ from healthy controls on these variables, (b) that these differences are subtler in RR 
patients relative to progressive subtypes, and (c) that PP and SP patients typically exhibit similar 
levels of these variables (De Sonneville et al., 2002).  Demographic and self-report variables that 
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yielded significant group differences were explored as potential covariates for subsequent GSH 
and neuropsychological analyses. 
 In addition to demographic and self-report variables, disease-related variables (MSNQ, 
EDSS, disease duration) were also assessed for group differences using omnibus tests, followed 
by Helmert comparisons for significant variables.  However, because these variables did not 
apply to controls, only the latter two Helmert contrasts (RR vs. progressive subtypes: PP vs. SP) 
were employed. 
 GSH and Neuropsychological Analyses.  MRS data acquisition yielded GSH 
concentrations for three regions of interest: frontal, parietal, and combined frontoparietal.  
Neuropsychological assessment yielded 13 scores organized into three MS-relevant cognitive 
domains: processing speed, memory, and executive functioning.  As in the case with 
demographic and self-report variables, group differences (controls, RR, PP, SP) for GSH 
concentrations and neuropsychological scores were evaluated using omnibus tests followed by 
Helmert contrasts.  Additionally, Hedges’ g effect sizes for each contrast were examined in order 
to identify the neuropsychological measures and GSH regions that yielded the largest group 
differences. 
 Correlational Analyses.  With only patients being considered, associations between 
GSH concentrations and neuropsychological measures were calculated using Pearson product-
moment correlations.  Additionally, correlations between GSH concentrations and disease related 
variables were explored using Pearson product-moment correlations for MSNQ and disease 
duration and Spearman rank-order correlations for EDSS. 
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Results 
Initial Group Differences 
 Means and standard deviations for all groups on continuous demographic, self-report, and 
disease-related variables are presented in Table 1.  Groups did not differ with respect to gender 
(Χ2 (3, N = 65) = 7.33, p = .06, Cramer’s V = .34); however, an omnibus multivariate analysis of 
variance (MANOVA) revealed statistically significant group differences for age (F(3, 61) = 6.54, 
p < .001, η2 = .24), years of education (F(3, 61) = 3.18, p < .05, η2 = .14), depression (BDI-FS: 
F(3, 61) = 6.93, p < .001, η2 = .25), fatigue (FSS: F(3, 61) = 14.51, p < .001, η2 = .42), and 
perceived stress (PSS: F(3, 61) = 5.27, p < .01, η2 = .21).  Additionally, the three patient groups 
differed on disability status (EDSS: F(2, 43) = 44.25, p < .001, η2 = .67) and disease duration 
(F(2, 43) = 4.95, p < .05, η2 = .19), but not subjective cognitive impairment (MSNQ: F(2, 43) = 
1.55, p = .23, η2 = .07).  Results of Helmert contrasts for significant initial variables are 
presented in Table 2.  MS patients as a whole reported significantly greater levels of depression, 
fatigue, and stress relative to controls.  Furthermore, patients with progressive subtypes were 
older, reported greater levels of depression and fatigue, and had greater disability ratings and 
longer disease durations than RR patients.  Education comprised the only difference between PP 
and SP patients, with PP patients obtaining fewer years of education than SP patients. 
 Because of these initial group differences, age, education, BDI-FS, FSS, and PSS were 
examined as potential covariates using separate multivariate analyses of covariance 
(MANCOVAs).  For GSH measures, none of these initial variables comprised significant 
covariates (all ps > .05).  For neuropsychological test performance, fatigue and stress did not 
emerge as significant covariates (all ps > .05).  Age was a significant covariate for performance 
on the Stroop-RI; education was a significant covariate for performance on eight 
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neuropsychological measures: Rey-DRRT, Stroop-W, Stroop-C, Stroop-WC, SDMT, Rey-A, 
Rey-IR, and Rey-DR; and BDI-FS emerged as a significant covariate for Stroop-C and SDMT 
performance.  However, when these covariates were omitted and the analyses repeated, group 
differences on neuropsychological measures were nearly identical.  Therefore, these variables 
were not included as covariates in subsequent analyses. 
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Table 1 
Means and Standard Deviations of Demographic, Self-Report, and Disease-Related Variables 
  CNTL (N=19)  
RR 
(N=15)  
PP 
(N=15)  
SP 
(N=16) 
  M SD  M SD  M SD  M SD 
Age  47.79 11.73  39.67 9.54  54.13 7.59  51.56 8.36 
Education (yrs)  15.53 1.90  15.07 1.58  14.07 1.58  15.94 1.98 
BDI-FS  0.84 1.77  1.93 2.02  4.07 3.73  4.38 2.87 
FSS  1.82 0.72  3.24 1.76  4.19 1.70  4.82 1.47 
PSS  9.58 4.75  13.80 7.76  15.27 8.36  19.25 8.10 
MSNQ  --- ---  18.33 9.83  25.73 13.78  23.69 11.81 
EDSS  --- ---  1.87 0.69  5.83 1.16  5.63 1.78 
Duration (yrs)  --- ---  8.13 4.84  10.67 7.04  15.06 6.54 
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Table 2 
Helmert Contrasts for Significant Demographic, Self-Report, and Disease-Related Variables 
  Contrast Estimates 
  CNTL vs All MS  RR vs (PP+SP)  PP vs SP 
Age  -.67  -13.18***  2.57 
Education (yrs)  0.50  0.07  -1.87** 
BDI-FS  -2.62***  -2.29**  -0.31 
FSS  -2.27***  -1.26**  -0.63 
PSS  -6.53**  -3.46  -3.98 
EDSS  ---  -3.86***  0.21 
Duration (yrs)  ---  -4.73*  -4.40 
*p < .05. **p < .01. ***p < .001 
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GSH Concentrations 
 Mean GSH levels (frontal, parietal, and frontoparietal) for each group are depicted in 
Figure 2.  Groups differences were observed for all three regions of interest (frontal: (F(3, 42) = 
4.54, p < .01, η2 = .25); parietal: (F(3, 42) = 2.99, p < .05, η2 = .18); frontoparietal: (F(3, 42) = 
4.68, p < .01, η2 = .25).  Helmert contrasts and Hedges g effect sizes for each region are 
presented in Table 3.  For all three regions, GSH concentrations were significantly lower for MS 
patients than controls.  Additionally, frontal and frontoparietal GSH levels were lower for 
progressive patients than for RR patients.  No other significant group differences were observed.  
Hedges’ g effect sizes for significant contrasts ranged from .81 to .98.  While all three regions of 
interest were effective at differentiating controls and MS patients, only frontal and frontoparietal 
GSH concentrations were effective at distinguishing RR from progressive patients. 
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Figure 2.  Comparison of GSH levels (means ± SEM) for Controls (n = 10), RR patients (n = 
12), PP patients (n = 13), and SP patients (n = 11). *p < .05. **p < .01. 
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Table 3 
Helmert Contrasts and Hedges’ g for Significant GSH Measures 
  
CNTL  
vs All MS  
RR 
vs (PP+SP)  
PP 
vs SP 
  Contrast g  Contrast g  Contrast g 
Frontal  0.08* .81  0.09** .98  -0.03 -1.09 
Parietal  0.09* .91  0.06 .58  -0.02 -.64 
Frontoparietal  0.08* .96  0.07* .91  -0.03 -.92 
*p < .05. **p < .01. ***p < .001 
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Neuropsychological Outcomes 
 Table 4 presents means and standard deviations for all groups on neuropsychological 
measures included in this study.  Groups did not differ significantly on any executive function 
scores (TOL-Score: (F(3, 61) = 2.51, p = .07, η2 = .11); TOL-PT (F(3, 61) = 1.34, p > .05, η2 = 
.27); Stroop-RI (F(3, 61) = 0.50, p = .68, η2 = .02).  However, group differences were significant 
for all other measures (all ps < .05), with eta-squared effect sizes ranging from .12 to .51.  
Helmert contrasts and Hedges g effect sizes for significant neuropsychological outcomes are 
presented in Table 5. 
 With regard to processing speed, MS patients as a whole performed more slowly than 
controls on all measures except the Stroop-W, and progressive patients performed more slowly 
than RR patients on all measures.  There were no differences between PP and SP subtypes.  
Hedges’ g effect sizes for significant contrasts ranged from .63 to 2.06.  Effect sizes for the 
single RT measure (Rey-DRRT) and the four RSP measures were approximately equivalent in 
terms of distinguishing patients from controls and PP from SP patients; however, all four RSP 
measures were more effective than the RT measure for distinguishing RR from progressive 
patients. 
 For measures of verbal and visual memory, Hedges’ g effect sizes for significant 
contrasts ranged from .52 to 1.50.  Although visual tasks were generally more effective than 
verbal tasks for distinguishing patients and controls, verbal tasks were more effective for 
distinguishing RR and progressive subtypes.  As in the case with processing speed measures, 
there were no differences between PP and SP subtypes. 
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Table 4 
Means and Standard Deviations of Neuropsychological Variables 
  CNTL (N=19)  
RR 
(N=15)  
PP 
(N=15)  
SP 
(N=16) 
  M SD  M SD  M SD  M SD 
Processing Speed             
     Rey-DRRT  1.75 0.76  1.81 0.50  2.67 0.88  3.06 2.20 
     Stroop-W  76.21 17.17  80.47 14.64  58.53 22.01  60.69 22.21 
     Stroop-C  64.47 9.61  67.13 10.23  47.80 14.89  49.06 17.09 
     Stroop-WC  140.68 24.60  147.60 21.18  106.33 36.17  109.75 37.84 
     SDMT  61.79 11.82  61.33 9.59  36.53 10.17  39.31 15.13 
             
Memory             
Verbal             
     Rey-A  27.00 5.71  29.00 6.29  20.80 5.45  22.56 6.26 
     Rey-IR  8.16 3.08  8.60 3.29  5.27 2.52  5.69 3.01 
     Rey-DR  44.26 3.87  44.53 4.05  41.20 3.84  41.25 4.49 
Visual             
     SDMT-IL  40.95 2.42  37.27 4.06  36.60 3.09  36.00 2.76 
     BVMT  28.11 7.20  26.07 7.15  21.60 7.87  20.19 7.09 
             
Executive Function             
     TOL-Score  11.68 1.67  12.47 2.13  11.27 2.12  10.44 2.50 
     TOL-PT  9.75 4.10  11.98 4.61  12.39 4.37  12.43 5.51 
     Stroop-RI  27.19 10.94  26.95 9.96  30.72 12.37  29.77 8.79 
 
32	  
Table 5 
Helmert Contrasts and Hedges’ g for Significant Neuropsychological Measures 
  
CNTL  
vs All MS  
RR 
vs (PP+SP)  
PP 
vs SP 
  Contrast g  Contrast g  Contrast g 
Processing Speed          
            Rey-DRRT  -0.77* -.66  -1.05** -.85  -0.39 -.23 
            Stroop-W  9.65 .50  20.86*** 1.12  -2.15 -.10 
            Stroop-C  9.81** .73  18.70*** 1.40  -1.26 -.08 
            Stroop-WC  19.46* .63  39.56*** 1.32  -3.42 -.09 
            SDMT  16.06*** 1.14  23.41*** 2.06  -2.78 -.22 
          
Memory          
     Verbal          
            Rey-A  2.88 .46  7.32*** 1.20  -1.76 -.30 
            Rey-IR  1.64* .52  3.12** 1.03  -0.42 -.15 
            Rey-DR  1.94 .48  3.31* .81  -0.05 -.01 
     Visual          
            SDMT-IL  4.33*** 1.50  0.97 .28  0.60 .20 
            BVMT  5.49** .75  5.17* .72  1.41 .19 
*p < .05. **p < .01. ***p < .001 
 
33	  
Correlations 
 Correlations between GSH concentrations and neuropsychological measures ranged from 
.07 to .52, from 0 to .43, and from .05 to .54 for frontal, parietal, and frontoparietal areas, 
respectively (Table 6).  Frontal GSH levels were positively correlated with performance on all 
RSP processing speed and verbal memory measures, with correlations for these measures 
ranging from .36 to .52.  Parietal GSH concentrations were positively correlated with the SDMT 
(r = .43), but not with any other scores.  Frontoparietal GSH levels were positively associated 
with performance on the Stroop-C, Stroop-WC, SDMT, Rey-A, and Rey-IR.  No significant 
correlations emerged for executive function measures.  For all three regions, RSP measures 
resulted in larger correlations than RT measures, and correlations for verbal memory tasks were 
larger than those for visual memory tasks. 
 Correlations between GSH concentrations and disease-related characteristics ranged from 
.06 to .36 (Table 6).  Frontal GSH concentrations were moderately correlated with MSNQ and 
frontoparietal concentrations were moderately correlated with EDSS.  There were no significant 
correlations between GSH concentrations and disease duration. 
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Table 6 
Correlations between GSH, Neuropsychological Measures, and Disease-Related Variables 
  GSH Regions of Interest 
  Frontal  Parietal  Frontoparietal 
Neuropsychological Measures       
Processing Speed       
          Rey-DRRT  -.22  -.29  -.29 
          TOL-PT  -.27  -.24  -.29 
          Stroop-W  .37*  .20  .32 
          Stroop-C  .36*  .26  .35* 
          Stroop-WC  .38*  .23  .35* 
          SDMT  .52***  .43**  .54*** 
Memory       
     Verbal       
          Rey-A  .44**  .31  .43** 
          Rey-IR  .47**  .31  .44** 
          Rey-DR  .44**  .10  .30 
     Visual       
          SDMT-IL  .25  .10  .19 
          BVMT  .20  .05  .14 
Executive Function       
          TOL-Score  .10  .12  .12 
          Stroop-RI  .07  .00  .05 
       
Disease-Related Characteristics        
          MSNQ  -.34*  -.20  -.32 
          EDSS†  -.29  -.30  -.36* 
          Disease Duration  -.23  .13  -.06 
†Spearman rank-order correlations. *p < .05. **p < .01. ***p < .001 
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Discussion 
 The present study featured the first comparison of cerebral GSH concentrations among 
patients with RR, PP, and SP subtypes of MS and healthy controls.  Consistent with our pilot 
study (Choi et al., 2011), frontal and frontoparietal GSH levels were lower for patients relative to 
controls.  Additionally, relative to controls and RR patients, progressive (PP and SP) patients 
exhibited the largest reductions in GSH concentrations, with no significant differences between 
PP and SP patients.  These results support the idea that even in the absence of acute clinical 
exacerbations (i.e., relapses), diffuse metabolic changes in GSH concentrations signal an 
ongoing neurodegenerative process that likely contributes to disease progression. 
 While the present study focused on GSH as one specific marker of diffuse 
neurodegeneration in MS, it is useful to consider whether other metabolites have exhibited 
similar patterns of outcomes among MS subtypes.  Several studies have investigated N-
acetylaspartate (NAA), a ubiquitous molecule that is found exclusively in neurons and serves as 
a marker of diffuse axonal injury (Kirov et al., 2009; Aboule-Enein et al., 2010).  Aboule-Enein 
and colleagues (2010) noted group differences in NAA that were very similar to those observed 
for GSH in the present study.  Specifically, SP patients exhibited the largest reductions in diffuse 
NAA concentrations relative to RR patients and controls.  The striking similarity between NAA 
and GSH profiles among MS patients, particularly with regard to progressive subtypes, provides 
further support for neurodegeneration as a major force driving disease progression beyond the 
relapsing episodes of multifocal inflammation in brain tissues that seems to characterize RR 
patients. 
 In addition to examining group differences in GSH concentrations, the present study also 
investigated whether these differences occurred in conjunction with neuropsychological 
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impairments.  The pattern of group differences on neuropsychological measures paralleled those 
for GSH concentrations, where progressive patients exhibited the most severe deficits, and no 
significant differences emerged between SP and PP patients.  Additionally, GSH concentrations 
significantly correlated with select RSP measures of information processing speed and with 
additional measures of verbal memory, suggesting that oxidative stress as reflected by reductions 
in GSH concentrations may be driving these forms of cognitive impairment commonly observed 
in MS. 
 Differences in neuropsychological performance are perhaps best discussed in terms of a 
worsening and broadening of impairments (De Sonneville et al., 2002).  These concepts are 
useful in conceptualizing the nature of cognitive impairment commonly observed over the course 
of MS.  With regard to worsening, deficits in information processing speed, particularly on RSP 
measures, are typically observed early in the disease course and worsen with disease progression 
(De Sonneville et al., 2002; Parmenter, Shucard, Benedict, & Shucard, 2006).  The emergence of 
processing speed deficits is generally attributed to the diffuse nature of MS pathology, where 
widespread axonal damage reduces the redundancy in connectivity that seems to characterize 
most tracts within the CNS, thereby detracting from the speed and efficiency of neuronal 
transmission (Kail, 1997; 1998).  In the present study, effect sizes for progressive patients 
relative to RR patients were quite large, providing at least suggestive evidence of this worsening.  
With regard to broadening, the limited spectrum of deficits observed early in the disease course 
expands to include impairments in other cognitive domains as the disease progresses (Amato, 
Ponziani, Siracusa, & Sorbi, 2001).  The emergence of these additional deficits is generally 
believed to be a consequence of more extensive neuronal injury, where redundancies in 
neurological tracts can no longer forestall the emergence of additional deficits in cognitive 
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operations (Bjartmar, Wujek, & Trapp, 2003).  The present findings supported evidence for 
broadening, with the addition of two verbal memory deficits (Rey-A and Rey-DR) in progressive 
patients. 
 It is important to note that no differences were found between groups on any of the 
executive function measures; thus, the concepts of “worsening” and “broadening” did not appear 
to apply to this cognitive domain.  This finding highlights one of the major inconsistencies 
within the MS literature.  Whereas some investigators have cited evidence for executive function 
deficiencies (e.g., Beatty, Hames, Blanco, Paul, & Wilbanks, 1995; Heaton et al., 1985; Nilsson, 
Rorsman, Larson, Norrving, & Sandberg-Wollheim, 2008), others, including our own research 
group (Drew, Tippett, Starkey, & Isler, 2008; Helekar et al., 2010; Denney, Lynch, & Parmenter, 
2008; Denney, Lynch, Parmenter, & Horne, 2004; Denney et al., 2011), have consistently failed 
to find these differences.  A meta-analysis by Zakzanis (2000) attempted to resolve this issue, 
suggesting that while executive deficits are present in MS, they do not typically emerge until 
later stages of the disease.  Even so, this conclusion conflicts with studies that have demonstrated 
executive dysfunction quite early in the disease process (Schulz, Kopp, Kunkel, & Faiss, 2006).  
Several investigators (Denney et al., 2011; DeLuca, Chelune, Tulsky, Lengenfelder, & 
Chiaravalloti, 2004) have suggested that impairments in executive function observed in MS 
patients may be better explained as an artifact of more basic deficits in processing speed, where 
executive function deficits emerged only when assessments were confounded with speed.  For 
example, while Denney and Lynch (2009) found differences in the naming of print colors on 
incongruent Stroop stimuli, a measure of executive function (attentional control) that is 
confounded with speed, no group differences remained after statistically controlling for speed.  
This hypothesis was also supported in a study using the TOL (Owens, Denney, and Lynch, 
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2012), where patients performed worse than controls when the TOL was administered under 
explicit time constraints, but not under untimed conditions.  Because the present study used an 
untimed version of the TOL, the lack of group differences observed on this measure, as well as 
on the Stroop-RI, supported the notion that executive dysfunction is not a hallmark deficit among 
MS patients at any stage of the disease. 
 While significant differences emerged between RR and progressive subtypes, no 
significant differences were observed between PP and SP patients.  Therefore, it is possible that 
these two subtypes may be pathologically indistinguishable in terms of neurodegeneration, 
resulting in comparable GSH concentrations and neuropsychological test performance.  
Alternatively, given the relatively small sample sizes of 15 and 16 for PP and SP patients, 
respectively, it is possible that the present study lacked sufficient statistical power to detect 
differences in either GSH concentrations or neuropsychological test performance.  Some 
investigators have suggested that SP patients may have more severe neuropsychological deficits 
than PP patients as a function of typically longer disease durations; however, this distinction is 
rather tenuous given that the measurement of disease duration generally begins when patients 
exhibit distinct episodes involving inflammatory processes and for PP patients, such episodes 
may be clinically “silent” and therefore undiagnosed. 
 In addition to small sample sizes, several limitations deserve mention.  First, all of the 
patients who participated in this study were required to have cognitive abilities sufficient for 
understanding the instructions for neuropsychological assessments.  Approximately 10 patients 
were screened as ineligible on the basis of prohibitive cognitive impairment during the 
recruitment phase of the study.  Therefore, we cannot discount the possibility that executive 
dysfunction might have been evident in these excluded patients, and that these deficits would 
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have been correlated with GSH concentrations.  Second, additional metabolic markers (e.g., 
NAA) and structural measures (e.g., global atrophy; lesion burden) of neurodegeneration were 
not included in the present study.  Therefore, we cannot establish the relationship between GSH 
reductions and these other more firmly established markers of neurodegeneration in this sample.  
Finally, it is not entirely clear whether GSH concentrations provide a dynamic marker of active, 
ongoing neurodegeneration, or a more static marker of the total neurodegeneration accumulated 
over time (Choi et al., 2011).  An analogous comparison might be made for the difference 
between daily blood glucose measurements and glycated hemoglobin (A1c) testing in patients 
with diabetes mellitus, where daily measurements provide a better dynamic marker of blood 
glucose changes and A1c levels provide a better summative marker of blood glucose control.  
While the former would be more useful for detecting the initiation of neurodegenerative 
processes, the latter would be more relevant in examining neurodegenerative changes over time. 
 In light of these limitations, future work in this area would benefit from including 
information concerning other brain metabolites and structural MRI scans.  Additionally, a 
longitudinal study, with particular focus on GSH levels in RR patients who over time develop SP 
MS versus those who never undergo this conversion could provide valuable insight into whether 
GSH constitutes a dynamic or static marker of neurodegeneration as well as the predictive value 
of this marker in terms of future changes in clinical status.  Comparative GSH concentrations in 
these groups could further clarify the role of oxidative stress-mediated neurodegeneration and the 
neurological and neuropsychological sequelae of this process. 
 In conclusion, the present study examined the role of oxidative stress-mediated 
neurodegeneration among patients with RR, PP, and SP MS and healthy controls.  Reductions in 
diffuse cerebral GSH concentrations were accompanied by a worsening of impairment in 
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processing speed and a broadening of impairment to include deficits in learning and memory, 
and importantly, these impairments were more pronounced in PP and SP patients than in RR 
patients.  As such, the present findings suggest that oxidative stress-mediated neurodegeneration 
comprises an event driving disease progression and related neuropsychological impairments in 
the later stages of MS. 
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